Add articles, eBooks or videos to your Library.
You can revisit, watch or read your favorite items later
You can revisit, watch or read your favorite items later
The U.S. Food and Drug Administration's (FDA) staff on Tuesday raised concerns over the safety of Spectrum Pharmaceutical's experimental cancer drug and questioned the benefits it provided over existing therapies, dragging its shares 30%.